'Master switch' experimental drug could treat different cancers

July 11, 2012
'Master switch' experimental drug could treat different cancers

(Medical Xpress) -- A unique multi-target experimental drug could treat a range of cancer types, according to research published in Clinical Cancer Research today.

Cancer Research UK-funded work at The Institute of Cancer Research in London shows that AT13148 – a type of drug called a kinase inhibitor – operates like a master switch to simultaneously block several different enzymes that control cancer cell growth and cell death.

Many kinase inhibitors have been developed that block only a single enzyme, but so far these drugs have shown only limited effectiveness. Scientists hope that switching off cell signals at multiple points could make the drug more likely to benefit patients and also delay drug resistance.

Laboratory tests showed that AT13148 was able to kill a range of cancer cell types including sarcoma, breast and prostate.

Lead author Dr. Michelle Garrett, team leader in the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, said: “Our study shows that this drug is effective against a range of tumour types, and operates by blocking multiple targets. These promising results have led to the decision to take the drug into patient trials.”

The molecule was originally discovered by scientists on the PKB discovery program, a collaboration between Astex Pharmaceuticals, Cancer Research Technology and The Institute of Cancer Research, which ran from 2003 through to 2006. The collaboration generated a series of compounds, of which a preferred candidate was then selected.

Dr. Julie Sharp, Cancer Research UK’s senior science information manager, said: “This is exciting research showing that this does the job of several drugs all at once, by targeting numerous weak spots in cancer cells.

“Using one to turn off the different faulty messages forcing cells to keep growing could be an effective way to destroy tumours. It could also reduce the chance of patients becoming resistant to treatment."

Explore further: CRT unveils 'screen test' for potential drugs to treat oestrogen positive breast cancer

More information: Yap et al. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumour activity. Clinical Cancer Research (2012). DOI: 10.1158/1078-0432.CCR-11-3313

Related Stories

CRT unveils 'screen test' for potential drugs to treat oestrogen positive breast cancer

March 6, 2012
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.

Gene silencing paves way to new treatments for breast cancer

October 21, 2011
(Medical Xpress) -- Cancer Research UK scientists have discovered that switching off a gene called CERT makes breast cancer cells more sensitive to a range of drugs. The research is published in the Journal of Pathology.

Class of breast cancer drugs could treat other types of cancer

November 9, 2011
(Medical Xpress) -- A class of drugs used to treat breast cancers which overproduce a protein called HER2 could also treat other types of cancer – particularly head and neck cancers, according to research presented at ...

Scientists find new drug target for hard-to-treat leukaemia

March 30, 2012
(Medical Xpress) -- Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival, according to research ...

Breakthrough could make 'smart drugs' effective for many cancer patients

June 27, 2011
(Medical Xpress) -- Newcastle and Harvard University reseachers have found that blocking a key component of the DNA repair process could extend the use of a new range of 'smart' cancer drugs called PARP inhibitors.

Drug combination domino effect destroys pancreatic cancer cells

February 22, 2012
(Medical Xpress) -- Cancer Research UK scientists have revealed how a combination of two very different drugs – currently being tested in clinical trials – amplifies the destruction of pancreatic cancer cells, according ...

Recommended for you

Researchers discover how enzyme 'shape-shifts' in drug-resistant leukemia

September 26, 2017
St. Jude Children's Research Hospital structural biologists have deciphered how the structure of the enzyme called Abl regulates its activity, enabling the enzyme to switch itself on and off. Understanding Abl's regulation ...

Researchers identify gene variants linked to a high-risk children's cancer

September 25, 2017
Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery may assist doctors in better diagnosing ...

Prostaglandin E1 inhibits leukemia stem cells

September 25, 2017
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.

MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer

September 25, 2017
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing ...

Cancer vaccines need to target T cells that can persist in the long fight against cancer

September 25, 2017
Cancer vaccines may need to better target T cells that can hold up to the long fight against cancer, scientists report.

Lung cancer treatment could be having negative health effect on hearts

September 25, 2017
Radiotherapy treatment for lung cancer could have a negative effect on the health of your heart new research has found.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.